ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device

From: "BlindNews Mailing List" <BlindNews@xxxxxxxxxxxxxxx>
To: <BlindNews@xxxxxxxxxxxxx>
Date: Tue, 9 Oct 2007 10:11:45 -0400

PR Newswire
Tuesday, October 09, 2007

ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the
Newest Version of its ReBuilder Neuropathy Treatment Device

By Press Release

Expects Sales to Increase 30%

CHARLES TOWN, W.Va., Oct. 9 /PRNewswire/ -- ReBuilder Medical
Technologies, Inc. (Pink Sheets: RBRM) today announced a contract with ETS,
Inc of Albuquerque NM (http://www.etsnm.com) to manufacture an updated
version of the ReBuilder System(R), the Professional Model 2407. ETS is an
FDA-registered contract manufacturer for electronic device companies,
including electronic glucose monitors, blood pressure cuffs and microwave
ovens containing voice synthesizers to assist visually impaired diabetics.

For the past six months, ReBuilder Medical Technologies, Inc. and ETS
have been in negotiations while ETS completed its research and development
of the ReBuilder System(R) 2407 model, implementing valuable improvements
for the device. The prototype of the newer model, which features larger
knobs that are easier to adjust for those suffering from neuropathy, and a
third treatment modality, has been approved, and ETS has now begun
production, with the first units shipped to customers within the next 10
days.

The ReBuilder System(R) treats peripheral neuropathy, a side effect of
diabetes, and has a success rate that tops 90%. It is also beneficial in
treatment of restless leg syndrome (RLS). Providing service to diabetics
suffering the most advanced symptoms will increase sales by 30% and as we
penetrate the RLS market, we should see sales increasing over 45% per year
for the next few years. These are patients who have become accustomed to
dependence on others and are thrilled to be able to treat themselves in a
way that is suitable for their unique circumstances," said Dr. Phillips.

About ReBuilder Medical Technologies, Inc.:
ReBuilder Medical Technologies, Inc. is a manufacturer of medical
devices and innovative technologies founded by world-renowned medical
device inventor David B. Phillips, Ph.D. The company's flagship product is
its FDA registered ReBuilder System(R), used for treating peripheral
neuropathy. Unlike current therapies for neuropathy (nerve disease) that
depend on prescription drugs with powerful side effects, the ReBuilder
System(R) is a portable, battery-powered medical product that provides a
unique, non-surgical treatment which is non-invasive, has no side effects
and can actually strengthen muscles while increasing blood flow.

ReBuilder Medical Technologies, Inc. also manufactures the Phillips
Molluscum Treatment System(TM) for treating the skin disease Molluscum
Contagiosum which primarily affects children. This system uses its
proprietary form of micronized amorphous silver ions to disable the
molluscum pathogen without side effects. The company is currently
performing research and development on a number of other products as well.

ReBuilder Medical Technologies, Inc. is located in Charles Town, WV.
CEO, Dr. David Phillips, Ph.D. is best known for inventing the very first
infrared ear thermometer. Dr. Phillips also was responsible for the GST
System, which is used for the early detection of breast cancer, and the
AcuPen, a hand-held device that provides the benefits of acupuncture
without the use of needles.

More information on ReBuilder Medical Technologies, Inc. and its
products can be found at: http://www.rebuildermedical.com.

Safe Harbor: This letter contains certain forward-looking statements
within the meaning of Section 27A of the Securities Act of 1933, as amended
and Section 21E of the Securities Exchange Act of 1934, as amended, which
are intended to be covered by the safe harbors created thereby. Investors
are cautioned that all forward-looking statements involve risks and
uncertainty, including without limitation, the ability of the Company to
successfully implement its turnaround strategy, changes in costs of raw
materials, labor, and employee benefits, as well as general market
conditions, competition and pricing. Although the Company believes that the
assumptions underlying the forward-looking statements contained herein are
reasonable, any of the assumptions could be inaccurate, and therefore,
there can be no assurance that the forward-looking statements included in
this letter will prove to be accurate. In light of the significant
uncertainties inherent in the forward-looking statements included herein,
the inclusion of such information should not be regarded as representation
by the Company or any other person that the objectives and plans of the
Company will be achieved. In assessing forward-looking statements included
herein, readers are urged to carefully read those statements. When used in
the Annual Report on Form 10-K, the words "estimate," "anticipate,"
"expect," "believe," and similar expressions are intended to be
forward-looking statements.

SOURCE ReBuilder Medical Technologies, Inc.
Related links:
http://www.etsnm.com
http://www.rebuildermedical.com

Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20061128/REBUILDERLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@xxxxxxxxxxxxxx

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/10-09-2007/0004678305&EDATE=
BlindNews Mailing List
Subscribe: BlindNews-Request@xxxxxxxxxxxxx with "subscribe" as subject

ReBuilder Medical Technologies, Inc. Contracts with ETS to Manufacture the Newest Version of its ReBuilder Neuropathy Treatment Device

Other related posts: